Europe Preimplantation Genetic Diagnosis Market Size Study, by Test Type (Chromosomal Abnormalities, Aneuploidy, X-linked diseases, Single Gene Disorders, HLA Typing, Gender selection, Others) and Country Forecasts 2022-2032

Europe Preimplantation Genetic Diagnosis Market Size Study, by Test Type (Chromosomal Abnormalities, Aneuploidy, X-linked diseases, Single Gene Disorders, HLA Typing, Gender selection, Others) and Country Forecasts 2022-2032

Europe Preimplantation Genetic Diagnosis Market is valued at approximately USD 19.47 million in 2023 and is anticipated to grow with a healthy growth rate of more than 10.94% over the forecast period 2024-2032. Preimplantation Genetic Diagnosis (PGD) is a sophisticated reproductive technology used with In Vitro Fertilization (IVF) to screen embryos for genetic conditions before implantation. This enhances the chances of having a healthy child for couples at risk of transmitting genetic disorders. IVF involves stimulating the ovaries with hormones, retrieving mature eggs, and fertilizing them in a lab. Embryos are grown to the blastocyst stage, biopsied, and analyzed for genetic abnormalities. Only healthy embryos are selected for transfer to the uterus. PGD reduces genetic disorder transmission, improves IVF success rates, and raises ethical concerns about embryo selection and genetic privacy. It benefits couples with a family history of genetic disorders, recurrent miscarriages, or genetic-related fertility issues, marking a major advancement in reproductive medicine. The Europe Preimplantation Genetic Diagnosis Market is growing due to the adoption of next-generation sequencing (NGS) technologies, rising awareness and acceptance of genetic testing, and the integration of AI and machine learning. Supportive government policies, increased fertility clinics, and IVF procedures further drive market expansion.

The Europe Preimplantation Genetic Diagnosis (PGD) market is driven by increasing awareness and acceptance of genetic testing, fueled by better education and information. Advancements in genomic technologies have enhanced the accuracy and efficiency of PGD, allowing precise identification of genetic abnormalities and boosting IVF success rates. Supportive government policies and funding for genetic research promote PGD adoption. The rising prevalence of genetic disorders prompts more couples to seek PGD services. The growing number of fertility clinics and demand for IVF procedures, driven by delayed childbearing and infertility issues, contribute to market growth. Enhanced public and private investments in genetic research and healthcare infrastructure further support market expansion. However, the market faces restraints such as high PGD procedure costs, ethical concerns, and stringent regulatory frameworks in certain countries. Limited accessibility and awareness in some regions also pose challenges.

The key countries considered for the Europe Preimplantation Genetic Diagnosis market study include UK, Germany, France, Italy, Spain, and the Rest of Europe. Germany is the dominating region in terms of revenue in the Europe Preimplantation Genetic Diagnosis (PGD) Market due to its advanced healthcare infrastructure, high adoption rates of genetic testing, and strong governmental support. The country's well-developed healthcare system includes state-of-the-art facilities and a robust network of fertility clinics and genetic testing centres. Germany also has a high level of awareness and acceptance of genetic testing, with significant public uptake. Supportive government policies and funding for genetic research and reproductive health services further bolster Germany's position. On the other hand, the market in the UK is expected to develop at the fastest rate over the forecast period.

Major market players included in this report are:
Agena Bioscience Gmbh
Centogene Ag
Igenomix S.L
Embryolab S.A
Genetracer Biotech S.L
Generalife S.R.L.
Diatech Pharmacogenetics S.R.L.
Genoma Normteile Gmbh
Nij Geertgen Center for Fertility
Care Fertility Group Ltd

The detailed segments and sub-segments of the market are explained below:

By Test Type
Chromosomal Abnormalities
Aneuploidy
X-linked diseases
Single Gene Disorders
HLA Typing
Gender selection
Others
By Region:
Europe
UK
Germany
France
Spain
Italy
ROE

Years considered for the study are as follows:
Historical year – 2022
Base year – 2023
Forecast period – 2024 to 2032

Key Takeaways:
Market Estimates & Forecast for 10 years from 2022 to 2032.
Annualized revenues and Country level analysis for each market segment.
Detailed analysis of geographical landscape with Country level analysis.
Competitive landscape with information on major players in the market.
Analysis of key business strategies and recommendations on future market approach.
Analysis of competitive structure of the market.
Demand side and supply side analysis of the market.

Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.